Empagliflozin study for kidney and belly membrane function
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests whether empagliflozin improves kidney health and the function of the belly’s dialysis membrane in people with end-stage kidney disease who do peritoneal dialysis. It may help by changing how well the peritoneal dialysis system works and how the kidneys perform over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently doing peritoneal dialysis (PD) and your PD catheter is working reliably
- You have been on PD for more than 3 months and your PD schedule is stable
- You have not used an SGLT2 inhibitor (this medicine class) in the last 30 days
- You have not had peritonitis in the last 6 months and your PD catheter is not infected
- Your hemoglobin is at least 8 g/dL (not too anemic), and you can follow the study plan and consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
Hear when a new End Stage Renal Disease on Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.